$RLMD
RELMADA THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000121390023064519 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.24M $12.29M $11.83M
YoY Change 49.12% -15.84% 32.83%
% of Gross Profit
Research & Development $10.45M $13.74M $26.87M
YoY Change -65.76% -55.55% 6.31%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $22.69M $26.03M $38.70M
YoY Change -41.42% -42.81% 13.22%
Operating Profit -$22.69M -$26.03M
YoY Change -41.42% -42.81%
Interest Expense $690.0K $723.8K $758.1K
YoY Change -201.24% -193.45% -487.32%
% of Operating Profit
Other Income/Expense, Net $690.6K $723.8K $0.00
YoY Change -201.33% -87.02%
Pretax Income -$22.00M -$25.30M -$37.94M
YoY Change -44.19% -36.64% 10.37%
Income Tax
% Of Pretax Income
Net Earnings -$22.00M -$25.30M -$37.94M
YoY Change -44.18% -36.64% 10.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.73 -$0.84
Diluted Earnings Per Share -$1.31 -$0.84 -$1.26
COMMON SHARES
Basic Shares Outstanding 30.10M shares 30.10M shares 30.10M shares
Diluted Shares Outstanding 30.10M shares 30.10M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.3M $118.5M $148.3M
YoY Change -42.28% -44.08% -30.01%
Cash & Equivalents $6.699M $14.47M $5.396M
Short-Term Investments $99.60M $104.1M $142.9M
Other Short-Term Assets $2.800M $3.475M $4.035M
YoY Change -5.2% 1256.23% -64.3%
Inventory
Prepaid Expenses $2.834M $3.475M $4.035M
Receivables
Other Receivables $512.4K
Total Short-Term Assets $109.1M $122.0M $152.9M
YoY Change -41.69% -43.45% -31.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $47.72K $34.59K $34.88K
YoY Change 196.46% -1.84% 23.26%
Total Long-Term Assets $47.72K $34.59K $34.88K
YoY Change 196.46% -1.84% 23.26%
TOTAL ASSETS
Total Short-Term Assets $109.1M $122.0M $152.9M
Total Long-Term Assets $47.72K $34.59K $34.88K
Total Assets $109.1M $122.0M $152.9M
YoY Change -41.67% -43.44% -31.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.857M $4.854M $5.262M
YoY Change -72.6% -35.63% -52.99%
Accrued Expenses $5.565M $5.849M $7.207M
YoY Change -46.23% -48.61% 86.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.422M $10.70M $12.47M
YoY Change -59.46% -43.44% -17.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.422M $10.70M $12.47M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $8.400M $10.70M $12.47M
YoY Change -59.57% -43.44% -17.21%
SHAREHOLDERS EQUITY
Retained Earnings -$535.7M -$513.7M -$462.1M
YoY Change 26.3% 33.53% 51.48%
Common Stock $30.10K $30.10K $30.10K
YoY Change 5.09% 0.25% 8.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.7M $111.3M $140.4M
YoY Change
Total Liabilities & Shareholders Equity $109.1M $122.0M $152.9M
YoY Change -41.67% -43.44% -31.53%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$22.00M -$25.30M -$37.94M
YoY Change -44.18% -36.64% 10.37%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$11.63M -$13.27M -$35.88M
YoY Change -56.71% -38.62% -4.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.860M -$1.152M -$1.655M
YoY Change -87.77% 719.63% -98.18%
Cash From Investing Activities $3.860M -$1.152M -$1.655M
YoY Change -87.77% 719.63% -98.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 409.9K
YoY Change -100.0% -100.0% -99.75%
NET CHANGE
Cash From Operating Activities -11.63M -13.27M -35.88M
Cash From Investing Activities 3.860M -1.152M -1.655M
Cash From Financing Activities 0.000 0.000 409.9K
Net Change In Cash -7.770M -14.43M -37.13M
YoY Change -247.62% 87.98% -212.53%
FREE CASH FLOW
Cash From Operating Activities -$11.63M -$13.27M -$35.88M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Relmada Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5401931
dei Entity Address Address Line1
EntityAddressAddressLine1
2222 Ponce de Leon
dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Coral Gables
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33134
dei City Area Code
CityAreaCode
(786)
dei Local Phone Number
LocalPhoneNumber
629-1376
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
RLMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30099203 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14469354 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5395905 usd
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
104059737 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
142926781 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
512432 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3474540 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4035186 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
122003631 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
152870304 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34590 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34875 usd
CY2023Q2 us-gaap Assets
Assets
122038221 usd
CY2022Q4 us-gaap Assets
Assets
152905179 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4853616 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5261936 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5848850 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7206941 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10702466 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12468877 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3500000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30099203 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30099203 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099203 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099203 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
30099 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30099 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
625041121 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
602517138 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513735465 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-462110935 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111335755 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
140436302 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122038221 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152905179 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13740205 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30912671 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29601215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55925524 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12286521 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14599401 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24579120 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27883971 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
26026726 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
45512072 usd
us-gaap Operating Expenses
OperatingExpenses
54180335 usd
us-gaap Operating Expenses
OperatingExpenses
83809495 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26026726 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45512072 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-54180335 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-83809495 usd
CY2022Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
6351606 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
6351606 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1363406 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
387333 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2571037 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
717282 usd
CY2022Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
24502 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-666708 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
9480 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-639634 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1186337 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
651476 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-2949624 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
723772 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5577104 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2555805 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4128744 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25302954 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-39934968 usd
us-gaap Net Income Loss
NetIncomeLoss
-51624530 usd
us-gaap Net Income Loss
NetIncomeLoss
-79680751 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.73
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29935895 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29168511 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
140436302 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
11354466 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26321576 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
125469192 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
11169517 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25302954 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111335755 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
208264886 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
11930681 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
29583542 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300006 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64800 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39745783 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
210398132 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
12295016 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
595350 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
352744 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
13145057 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-39934968 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
196851331 usd
us-gaap Net Income Loss
NetIncomeLoss
-51624530 usd
us-gaap Net Income Loss
NetIncomeLoss
-79680751 usd
us-gaap Share Based Compensation
ShareBasedCompensation
22523983 usd
us-gaap Share Based Compensation
ShareBasedCompensation
24225697 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
6351606 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-666708 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9480 usd
rlmd Unrealizeds Lossgain On Shortterm Investments
UnrealizedsLossgainOnShorttermInvestments
651476 usd
rlmd Unrealizeds Lossgain On Shortterm Investments
UnrealizedsLossgainOnShorttermInvestments
-2949624 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-44143 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-512432 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
256192 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-560931 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7810846 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-408320 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2698790 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1358091 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7513045 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29778363 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41055884 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
45577832 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33412425 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
84429644 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
23244237 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38851812 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10168188 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42728599 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
417544 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
895356 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44041499 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9073449 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7182573 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5395905 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44443439 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14469354 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37260866 usd
CY2023Q2 rlmd Operating Cash Flows
OperatingCashFlows
29778363 usd
CY2023Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
513735465 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.</p>
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14469354 usd
CY2023Q2 us-gaap Shortterm Debt Fair Value
ShorttermDebtFairValue
104059737 usd
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
104059737 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-639634 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
651476 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1186337 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-2949624 usd
CY2023Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
706600 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15511297 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13511695 shares
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
600400 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
313.2 usd
CY2023Q2 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
2618600 usd
CY2022Q4 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
3619800 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
255500 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
102200 usd
CY2023Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
3474500 usd
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
4035200 usd
CY2023Q2 rlmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4590300 usd
CY2022Q4 rlmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5809800 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
149900 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
116500 usd
CY2022Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
492100 usd
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
328900 usd
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
529800 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
73200 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
258700 usd
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5848900 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7206900 usd
CY2022Q2 rlmd Aggregate Offering Price
AggregateOfferingPrice
100000000 usd
CY2014Q4 rlmd Common Stock Awards
CommonStockAwards
5152942 shares
CY2021Q2 rlmd Granted Options
GrantedOptions
1500000 shares
CY2022Q2 rlmd Granted Options
GrantedOptions
3900000 shares
CY2023Q2 rlmd Granted Options
GrantedOptions
2500000 shares
CY2023Q2 rlmd Granting To Option Or Stock Awards
GrantingToOptionOrStockAwards
13052942 shares
rlmd Stock Options Exercisable Period
StockOptionsExercisablePeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
rlmd Future Grant
FutureGrant
569086 shares
rlmd Vesting Term Year
VestingTermYear
P4Y
rlmd Aggregate Of Fair Value
AggregateOfFairValue
2100000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q2 rlmd Stock Based Compensation Expense
StockBasedCompensationExpense
74300000 usd
us-gaap Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1
NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1
P2Y5M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12122606 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
417998 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
680000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.53
rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
P9Y6M25D
rlmd Aggregate Intrinsic Value Outstanding And Expected To Vest Granted1
AggregateIntrinsicValueOutstandingAndExpectedToVestGranted1
900 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
157811 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
32.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
160939 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.16
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12483856 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.2
rlmd Weighted Average Remaining Contractual Term Years Ending Balance1
WeightedAverageRemainingContractualTermYearsEndingBalance1
P8Y1M2D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
900 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5601974 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.8
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q4 rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
3027441 shares
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
17.02
CY2023Q2 rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
3027441 shares
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
17.02
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2826191 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
15.91
CY2023Q2 rlmd Unrecognized Compensation Expense
UnrecognizedCompensationExpense
4700000
CY2023Q2 rlmd Intrinsic Value Of Warrant Vested And Outstanding
IntrinsicValueOfWarrantVestedAndOutstanding
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22524000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24225700 usd
CY2023Q2 rlmd Payment For License
PaymentForLicense
45000 usd
rlmd Fee Amount
FeeAmount
12700000 usd
us-gaap Short Term Lease Payments
ShortTermLeasePayments
160000000 usd
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
11000 usd
CY2021Q3 rlmd Lease Period
LeasePeriod
P5M
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-31
CY2022 us-gaap Payments For Rent
PaymentsForRent
9000 usd
us-gaap Payments For Rent
PaymentsForRent
13000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
137000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
44000 usd
CY2017Q2 us-gaap Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
7529 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
493452 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
397049 usd
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0838 pure
us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
96403 usd
us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.
rlmd Employee Contribution Expense
EmployeeContributionExpense
80900 usd
rlmd Employee Contribution Expense
EmployeeContributionExpense
62800 usd
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
rlmd Weighted Average Remaining Contractual Term Years Cancelled
WeightedAverageRemainingContractualTermYearsCancelled
rlmd Aggregate Intrinsic Value Cancelled
AggregateIntrinsicValueCancelled
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001553643

Files In Submission

Name View Source Status
0001213900-23-064519-index-headers.html Edgar Link pending
0001213900-23-064519-index.html Edgar Link pending
0001213900-23-064519.txt Edgar Link pending
0001213900-23-064519-xbrl.zip Edgar Link pending
f10q0623ex31-1_relmadatherap.htm Edgar Link pending
f10q0623ex31-2_relmadatherap.htm Edgar Link pending
f10q0623ex32-1_relmadatherap.htm Edgar Link pending
f10q0623ex32-2_relmadatherap.htm Edgar Link pending
f10q0623_relmadatherap.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0623_relmadatherap_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlmd-20230630.xsd Edgar Link pending
Show.js Edgar Link pending
rlmd-20230630_def.xml Edgar Link unprocessable
rlmd-20230630_lab.xml Edgar Link unprocessable
rlmd-20230630_pre.xml Edgar Link unprocessable
rlmd-20230630_cal.xml Edgar Link unprocessable